Apramycin

Medical uses

Apramycin can be used to treat bacterial infections in animals caused by Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa. The following shows susceptibility data on medically significant organisms:

• Escherichia coli - 1 μg/mL - 512 μg/mL (this large range may be due to resistant organisms, typical MIC values are likely in the range of 2 -8 μg/mL.
• Klebsiella pneumoniae - 2 μg/mL - 256 μg/mL
• Pseudomonas aeruginosa - 4 μg/mL

Mechanism of action

Traditional knowledge suggests that aminoglycosides bind to the bacterial ribosome, leading to misreading of mRNA and incorporation of incorrect amino acids in the nascent polypeptide chain. However, aminoglycosides, including apramycin, have been shown to not only cause misreading of the genetic code but also significantly slow down the overall rate of protein synthesis in live bacterial cells. This dual effect on both accuracy and efficiency of protein synthesis helps to explain the bactericidal properties of apramycin.

References

References

1. (3 August 2022). "Health product highlights 2021: Annexes of products approved in 2021".
2. (November 1977). "The in vitro activity of apramycin, a new aminocyclitol antibiotic". The Journal of Antimicrobial Chemotherapy.
3. "Apramycin". KnowledgeBase: The Antimicrobial Index.
4. (March 2021). "Real-time measurements of aminoglycoside effects on protein synthesis in live cells". Proceedings of the National Academy of Sciences of the United States of America.